Windlas Biotech Buyback 2026: Price, Record Date, Entitlement Ratio, Dates, Review
Last Updated: 2 May 2026 | 1.30 PM IST
Windlas Biotech Buyback 2026 – Overview
Windlas Biotech Ltd Buyback 2026 is a tender offer where the company plans to repurchase up to 4,70,000 equity shares (2.23% of total equity) at a price of Rs.1000 per share, aggregating to Rs.47.00 crore.
The buyback offers investors an opportunity to exit at a premium to the current market price, while the company aims to improve capital efficiency and reward shareholders.
Key Buyback Highlights
| Particulars | Details |
|---|---|
| Issue Type | Tender Offer |
| Issue Size (Shares) | 4,70,000 |
| Issue Size (%) | 2.23% |
| Buyback Size | Rs.47.00 Crore |
| Buyback Price | Rs.1000 per share |
| Face Value | Rs.5 |
| Listing | BSE, NSE |
Important Dates (Timetable)
| Event | Date |
|---|---|
| Record Date | April 24, 2026 |
| Offer Opens | April 30, 2026 |
| Offer Closes | May 7, 2026 |
| Last Date for Tender Forms | May 7, 2026 |
| Acceptance Finalisation | May 13, 2026 |
| Settlement of Bids | April 14, 2026 |
| Extinguishment of Shares | May 25, 2026 |
Eligibility:
Shareholders holding shares as on the record date are eligible to participate.
Entitlement Ratio
| Category | Entitlement Ratio | Shares Reserved |
|---|---|---|
| Small Shareholders | 1 : 18 | 97,342 |
| General Category | 1 : 18 | 3,72,658 |
Note:
- Small shareholders are classified as per Securities and Exchange Board of India (SEBI) regulations.
- Entitlement is calculated based on holdings on the record date.
Current Market Snapshot
| Parameter | Value |
|---|---|
| CMP | Rs.851.85 |
| Day High / Low | Rs.863 – Rs.850 |
| 52 Week High | Rs.1097.90 |
| 52 Week Low | Rs.697.40 |
| Trend | Stable with mild recovery |
Insight:
Buyback price of Rs.1000 indicates a ~17–18% premium over current levels, making it attractive for arbitrage-based participation.
Financial Performance
| Particulars (Rs. Cr.) | FY25 | FY24 |
|---|---|---|
| Assets | 760.45 | 626.21 |
| Total Income | 777.90 | 644.42 |
| PAT | 60.99 | 58.19 |
Analysis:
- Steady growth in revenue and profitability
- Strong balance sheet improvement
- Consistent earnings visibility supports buyback decision
Stock Price Trend (Last 3 Months)
BSE Data
| Month | High | Low | Avg |
|---|---|---|---|
| Mar 2026 | 785.00 | 699.35 | 742.00 |
| Feb 2026 | 967.00 | 748.95 | 805.78 |
| Jan 2026 | 962.00 | 735.00 | 796.51 |
NSE Data
| Month | High | Low | Avg |
|---|---|---|---|
| Mar 2026 | 786.00 | 697.40 | 740.88 |
| Feb 2026 | 928.50 | 746.00 | 805.70 |
| Jan 2026 | 950.00 | 735.30 | 795.72 |
Objective of Buyback
The company intends to:
- Return surplus cash to shareholders
- Improve earnings per share (EPS)
- Optimize capital structure
- Enhance long-term shareholder value
Intermediaries
| Role | Name |
|---|---|
| Manager | Fintellectual Corporate Advisors Pvt. Ltd. |
| Registrar | MUFG Intime India Pvt. Ltd. |
| Broker | SMC Global Securities Ltd. |
Company Details
Windlas Biotech Ltd
Mohabewala Industrial Area, Dehradun, Uttarakhand
The company operates in the pharmaceutical manufacturing space, focusing on contract development and manufacturing (CDMO) services with a growing domestic and export presence.
Chanakya View (Buyback Review)
Windlas Biotech Buyback 2026 appears moderately attractive:
Positives:
- Decent premium over CMP
- Stable financial performance
- Equal entitlement ratio across categories
Concerns:
- Small buyback size (2.23%)
- Limited upside if acceptance ratio falls
- Stock has shown recent volatility
Verdict:
Suitable for short-term arbitrage investors, while long-term investors may prefer holding based on fundamentals rather than tendering fully.
FAQs – Windlas Biotech Buyback 2026
Rs.1000 per share
April 24, 2026
1:18 for both retail and general category
Depends on acceptance ratio; currently offers decent premium
Shareholders holding shares on record date
Windlas Biotech Buyback 2026,
Windlas Buyback price,
Windlas Biotech entitlement ratio,
Windlas buyback record date,
Windlas Biotech tender offer details
Quicklinks